Last reviewed · How we verify

NCT03752437

Comparison of Two Dosages of Heparin Before Extracorporeal Circulation

Completed Phase 4 Last updated 15 February 2022
What this trial tests

Phase 4 trial testing ACT (Activated Clotting Time) in Extracorporeal Circulation; Complications in 150 participants. Completed in 30 September 2021.

Timeline
1 October 2019
Primary endpoint
30 September 2021
30 September 2021

Quick facts

Lead sponsorAstes
PhasePhase 4
StatusCompleted
Study typeINTERVENTIONAL
Allocationrandomized
Designparallel
Maskingtriple
Primary purposeother
Enrollment150
Start date1 October 2019
Primary completion30 September 2021
Estimated completion30 September 2021
Sites1 location across Belgium

Drugs / interventions tested

Conditions studied

Sponsor

Astes — full company profile →

Who can join

18 and older, any sex, with Extracorporeal Circulation; Complications. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

In this study the investigators will study two dosages of heparin before extracorporeal circulation in open chest cardiac surgery.

Publications & conference data

No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.

Verify or expand the search:

Other recruiting trials for Extracorporeal Circulation; Complications

Currently open trials in the same condition.

Other Astes trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03752437.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing